Underutilization of Genetic Testing for Homologous Recombination Repair Mutations in Metastatic Castration-Resistant Prostate Cancer Patients in the United States
Genetic testing for homologous recombination repair (HRR) mutations is underutilized in patients with metastatic castration-resistant prostate cancer (mCRPC) in the United States, despite its potential prognostic and predictive value for targeted therapies.